


Amendments to the Claims

The following listing of the claims will replace all prior versions and listings of claims in the application:

1-30 (canceled)

31. (currently amended) A compound according to formula I,



or a pharmaceutically acceptable salt or a stereoisomer, thereof, wherein,

A is a five- to ten-membered ring containing up to three heteroatoms; provided A is not a saturated alicyclic when X² is =N-, X³ is -O-, and A is a pyridin-4-yl;

R¹ is selected from -H, halo, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=O)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, alkoxy, C₁₋₆ alkyl, aryl, aryl C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl;

two adjacent of R¹, together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to four of R¹⁰;

R² and R³, together with the annular atoms to which they are attached, form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to five of R⁶;

each R⁴ is selected from -H; C₁₋₆ alkyl optionally substituted with 1, 2, or 3 halogen; C₁₋₆ alkyl optionally substituted with alkoxy; C₁₋₆ alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH₂CH₂OCH₃, -CH₂CH₂N(CH₃)₂, -CH₂CH₂CH₂N(CH₃)₂, and *N*-methyl-pyrrolidin-3-yl; aryl; aryl C₁₋₆ alkyl; heterocyclyl; and heterocyclyl C₁₋₆ alkyl where the heterocyclyl is

optionally substituted with alkyl, acyl, NH_2 , alkylamino, dialkylamino, heterocyclyl, cyclohexyl, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{C}(\text{O})\text{NHCH}(\text{CH}_3)_2$, or $-\text{CH}_2\text{OCH}_3$;

two of R^4 , when taken together with a common nitrogen to which they are attached, form an five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

each R^5 is selected from $-\text{H}$, $-\text{CN}$, $-\text{NO}_2$, $-\text{OR}^4$, $-\text{S}(\text{O})_{0.2}\text{R}^4$, $-\text{CO}_2\text{R}^4$, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl;

Y is $=\text{N}-$ or $=\text{C}(\text{H})-\text{C}(\text{R}^8)-$;

X^1 and X^2 are each independently either $=\text{N}-$ or $=\text{C}(\text{R}^9)-$;

X^3 is selected from $-\text{N}(\text{R}^7)-$, $-\text{O}-$, and $-\text{S}-$;

R^7 is hydrogen;

each of R^6 , R^8 , and R^{10} is independently selected from $-\text{H}$, halo, trihalomethyl, $-\text{CN}$, $-\text{NO}_2$, $-\text{OR}^4$, $-\text{N}(\text{R}^4)\text{R}^4$, $-\text{S}(\text{O})_{0.2}\text{R}^4$, $-\text{SO}_2\text{N}(\text{R}^4)\text{R}^4$, $-\text{CO}_2\text{R}^4$, $-\text{C}(=\text{O})\text{N}(\text{R}^4)\text{R}^4$, $-\text{C}(=\text{NR}^5)\text{N}(\text{R}^4)\text{R}^4$, $-\text{C}(=\text{NR}^5)\text{R}^4$, $-\text{N}(\text{R}^4)\text{SO}_2\text{R}^4$, $-\text{N}(\text{R}^4)\text{C}(\text{O})\text{R}^4$, $-\text{C}(=\text{O})\text{R}^4$, optionally substituted alkoxy, C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heterocyclyl, and heterocyclyl C_{1-6} alkyl;


two adjacent of R^6 , together with the annular atoms to which they are attached, can form a five- to seven-membered ring containing up to two heteroatoms; and

each R^9 is independently selected from $-\text{H}$; halo; trihalomethyl; $-\text{CN}$; $-\text{NO}_2$; $-\text{OR}^4$; $-\text{N}(\text{R}^4)\text{R}^4$; $-\text{S}(\text{O})_{0.2}\text{R}^4$; $-\text{SO}_2\text{N}(\text{R}^4)\text{R}^4$; $-\text{CO}_2\text{R}^4$; $-\text{C}(=\text{O})\text{N}(\text{R}^4)\text{R}^4$; $-\text{C}(=\text{NR}^5)\text{N}(\text{R}^4)\text{R}^4$; $-\text{C}(=\text{NR}^5)\text{R}^4$; $-\text{N}(\text{R}^4)\text{SO}_2\text{R}^4$; $-\text{N}(\text{R}^4)\text{C}(\text{O})\text{R}^4$; $-\text{C}(=\text{O})\text{R}^4$; alkoxy; C_{1-6} alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C_{1-6} alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with $-\text{C}(\text{O})\text{Ot-Bu}$; and heterocyclyl C_{1-6} alkyl; provided when R^9 is aryl, heteroaryl, $-\text{C}(\text{H})=\text{C}(\text{H})\text{R}$ or $-\text{C}(\text{H})=\text{NR}$, where R is an optionally substituted alkyl, cycloalkyl, heteroalicyclic, aryl, or heteroaryl, then Y is not $=\text{C}(\text{H})-$.

32. **(previously presented)** The compound according to claim 31, wherein the five- to six-membered ring formed by R^2 and R^3 is an aryl or a heteroaryl optionally substituted with up to five of R^6 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.

33. **(previously presented)** The compound according to claim 32, wherein the five- to six-membered ring formed by R^2 and R^3 is phenyl or pyridyl optionally substituted with up to five of R^6 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.

34. **(previously presented)** The compound according to claim 33, of formula II,



or a pharmaceutically acceptable salt or stereoisomer, thereof.

35. **(previously presented)** The compound according to claim 34, wherein X^1 is $=C(R^9)-$, X^2 is $=N-$, X^3 is $-N(R^7)-$, and R^7 is hydrogen; or a pharmaceutically acceptable salt or stereoisomer, thereof.

36. **(previously presented)** The compound according to claim 35, wherein Y is $=N-$; or a pharmaceutically acceptable salt or stereoisomer, thereof.


37. **(currently amended)** The compound according to claim 36, wherein A is either a six- to ten-membered aryl or a five- to ten-membered heteroaryl containing up to three heteroatoms and where A is substituted with 1-5 R^1 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.

38. **(currently amended)** The compound according to claim 37, wherein A is either a six-membered aryl or a five- or six-membered heteroaryl containing up to three heteroatoms and where A is substituted with 1-5 R^1 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.

39. **(previously presented)** The compound according to claim 38, wherein R^1 is selected from $-H$, halo, trihalomethyl, $-CN$, $-OR^4$, $-N(R^4)R^4$, $-SO_2N(R^4)R^4$, $-CO_2R^4$, $-C(=O)N(R^4)R^4$, $-C(=NR^5)N(R^4)R^4$, $-C(=NR^5)R^4$, $-N(R^4)SO_2R^4$, $-N(R^4)C(O)R^4$, alkoxy,

C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.


40. (previously presented) The compound according to claim 39, of formula III,



III

wherein R⁷ is hydrogen and at least one of R¹ is -OH; or a pharmaceutically acceptable salt or stereoisomer, thereof.

41. (previously presented) The compound according to claim 40, wherein the compound is either of Formula IIa or IIb:



or a pharmaceutically acceptable salt or stereoisomer, thereof.

42. (previously presented) The compound according to claim 41, wherein R⁹ is selected from -H; trihalomethyl; C₁₋₆ alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C₁₋₆ alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C₁₋₆ alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

43. (previously presented) The compound according to claim 42, wherein R⁶ is selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -C(=O)R⁴, C₁₋₆ alkyl, heterocyclyl, heterocyclyl C₁₋₆ alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R⁶, together

with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

44. **(previously presented)** The compound according to claim 43, wherein R^6 is selected from -H, halo, $-OR^4$, $-N(R^4)R^4$, C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R^6 , together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

45. **(previously presented)** The compound according to claim 44, wherein at least one of R^6 is $-OR^4$ and R^4 is C_{1-6} alkyl optionally substituted with 1, 2, or 3 halogen; C_{1-6} alkyl optionally substituted with alkoxy; C_{1-6} alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, $-CH_2CH_2OCH_3$, $-CH_2CH_2N(CH_3)_2$, $-CH_2CH_2CH_2N(CH_3)_2$, and *N*-methyl-pyrrolidin-3-yl; and heterocyclyl where the heterocyclyl is optionally substituted with alkyl, acyl, NH_2 , alkylamino, dialkylamino, heterocyclyl, cyclohexyl, $-CH_2OCH_3$, $-CH_2C(O)NHCH(CH_3)_2$, or $-CH_2OCH_3$; or a pharmaceutically acceptable salt or stereoisomer, thereof.

46. **(previously presented)** The compound according to claim 45, wherein at least one of R^1 is halo or methyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.


47. **(previously presented)** The compound according to claim 46, wherein R^9 is selected from -H, trihalomethyl, and C_{1-6} alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

48. **(previously presented)** The compound according to claim 44, wherein at least one of R^6 is $-OR^4$ and R^4 is heterocyclyl C_{1-6} alkyl where the heterocyclyl is a heteroalicyclic; or a pharmaceutically acceptable salt or stereoisomer, thereof.

49. **(previously presented)** The compound according to claim 48, wherein said heteroalicyclic is selected from the group consisting of dioxolanyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl,

azepinyl, 4-piperidonyl, pyrrolidinyl, morpholinyl, quinuclidinyl, tetrahydrofuryl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide, 2,5-diazabicyclo[2.2.1]heptanyl, and thiamorpholinyl sulfone; or a pharmaceutically acceptable salt or stereoisomer, thereof.

50. (currently amended) ~~The compound according to claim 44,~~ A compound according to Formula IIIa or IIIb



wherein

each R^1 is independently selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl;

R^9 is selected from -H; trihalomethyl; C₁₋₆ alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C₁₋₆ alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C₁₋₆ alkyl; and

wherein at least one of R^6 is -OR⁴ and R^4 is alkyl substituted with at least one additional of alkoxy, amino, dialkylamino, and monoalkylamino where the amino of the monoalkylamino is further substituted with *N*-methyl-pyrrolidin-3-yl and where each alkyl of monoalkylamino and dialkylamino are independently optionally substituted with -NH₂, -NHCH₃, or -N(CH₃)₂; or a pharmaceutically acceptable salt or stereoisomer, thereof.

51. (previously presented) The compound according to claim 31, selected from Table 3; or a pharmaceutically acceptable salt or stereoisomer, thereof

Table 3

Entry	Name	Structure
10	4-{7,8-bis(methyloxy)-1-[(4-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
12	4-(7,8-bis(methyloxy)-1-[(4-methyloxy)phenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
13	4-{7,8-bis(methyloxy)-1-[(2-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
14	4-{7,8-bis(methyloxy)-1-[(3-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
15	4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
20	4-[1-{{3,4-bis(methyloxy)phenyl}methyl}-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
21	4-(7,8-bis(methyloxy)-1-{{3-(methyloxy)phenyl}methyl}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
22	4-[1-ethyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
25	4-[1-methyl-6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
27	4-[7,8-bis(methyloxy)-1-(trifluoromethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3






Entry	Name	Structure
28	4-[1-(1-methylethyl)-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
29	4-[7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
31	4-[1-methyl-6,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
32	4-[6,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
34	4-[6,7,8-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3






Entry	Name	Structure
35	4-[1-methyl-7,8,9-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
36	4-[1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
37	2-methyl-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
38	4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-(methoxy)phenol	
39	4-{1-methyl-8-(methoxy)-7-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

Table 3

Entry	Name	Structure
40	2-(ethoxy)-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
41	2-chloro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
42	2-fluoro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
44	2-bromo-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
45	1-{{5-(4-hydroxyphenyl)-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-1-yl)methyl}pyrrolidin-2-one	

Table 3

Entry	Name	Structure
54	4-{1-methyl-7-(methyloxy)-8-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
55	4-{1-methyl-8-(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
58	4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
59	4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
60	4-[7-(ethyloxy)-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
61	4-{1-methyl-8-(methyloxy)-9-[(piperidin-4-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
63	2-ethyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
64	4-(1-methyl-8-(methyloxy)-9-[[1-methylpiperidin-4-yl)methyl]oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
65	4-(1-methyl-7-(methyloxy)-8-[[1-methylpiperidin-4-yl)methyl]oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
66	4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
67	1,1-dimethylethyl 4-[5-(4-hydroxyphenyl)-7,8-bis(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-1-yl]piperidine-1-carboxylate	
69	2-chloro-4-[1-methyl-8,9-bis(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
70	2-fluoro-4-[1-methyl-8,9-bis(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
71	2-methyl-4-[1-methyl-8,9-bis(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
72	2-bromo-4-[1-methyl-8,9-bis(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
76	2-[(difluoromethyl)oxy]-4-[1-methyl-7,8-bis(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
78	4-[1,9-dimethyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
79	4-[6,9-difluoro-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
80	2-bromo-4-{1-methyl-8-(methoxy)-9-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
81	2-chloro-4-{1-methyl-8-(methoxy)-9-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
82	4-(7,8-bis(methoxy)-1-[[[(phenylmethyl)amino]methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
83	2,5-dimethyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
85	2,5-dichloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
87	2-bromo-4-(1-methyl-8-(methyloxy)-9-[[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
88	2-chloro-4-(1-methyl-7-(methyloxy)-8-[[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
89	4-[9-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
90	4-(1-methyl-8-(methyloxy)-9- {[2-(methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	
91	2-chloro-4-(1-methyl-8- (methyloxy)-9-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	
92	4-[6-bromo-1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
93	4-[6-fluoro-1-methyl-7,8- bis(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	
94	4-[9-chloro-1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
95	2-chloro-4-[8-{{(1-ethylpiperidin-4-yl)methyl}oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
96	3-chloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
97	4-(1-methyl-8,9-bis{{2-(methyloxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
98	4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
99	2-chloro-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
100	2-bromo-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
101	2-chloro-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
102	2-bromo-4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
103	2-chloro-4-[1-methyl-8-({[1-(1-methylethyl)piperidin-4-yl]methyl}oxy)-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
104	4-[9-bromo-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
105	4-[7-chloro-9-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3






Entry	Name	Structure
106	4-[8-{{[(1-acetyl)piperidin-4-yl)methyl]oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
107	4-[9-{{[(1-acetyl)piperidin-4-yl)methyl]oxy}-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-bromophenol	
108	2-chloro-4-(1-methyl-9-(methyloxy)-8-{{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl})phenol	
109	4-[7-fluoro-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
110	2-chloro-4-(1-methyl-8,9-bis{{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl})phenol	

Table 3

Entry	Name	Structure
111	2-bromo-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
112	2-chloro-4-(1-methyl-8-(methyloxy)-9-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
113	2-bromo-4-(1-methyl-8-(methyloxy)-9-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
114	3-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
115	2-chloro-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
116	2-bromo-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
117	2-chloro-4-(1-methyl-7,8-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
118	2-bromo-4-(1-methyl-7,8-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
120	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
121	2-chloro-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
122	2-bromo-5-fluoro-4-[1-methyl-7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
123	4-[9-fluoro-1-methyl-7,8-bis(methoxy)-3 <i>H</i> -benzo[<i>e</i>]indazol-5-yl]phenol	
125	3-fluoro-4-(1-methyl-7-(methoxy)-8-{{2-(methoxy)ethyl}oxy})-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
126	4-(6,9-difluoro-1-methyl-8-{{2-(methoxy)ethyl}oxy})-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-3-fluorophenol	
127	2-chloro-4-(6,9-difluoro-1-methyl-8-{{2-(methoxy)ethyl}oxy})-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
128	2-chloro-4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
129	2-chloro-4-[6-chloro-1-methyl-7,8-bis(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
130	3-fluoro-4-(1-methyl-9-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	
131	2-chloro-4-(1,7-dimethyl-8-{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	
132	3-fluoro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
133	2-chloro-4-[1-methyl-8-[(1-methylethyl)oxy]-7-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
134	2-chloro-4-{1-methyl-7-(methoxy)-8-[(2-methylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
135	2-bromo-5-fluoro-4-(1-methyl-7-(methoxy)-8-{[2-(methoxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
136	4-[7,8-bis(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
137	4-[7,8-bis(methoxy)-1-(trifluoromethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	

Table 3






Entry	Name	Structure
138	4-{7,8-bis(methoxy)-1-[(methoxy)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}-2-chlorophenol	
139	2-chloro-4-(1-methyl-3 <i>H</i> -[1,3]dioxolo[4,5- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
140	2-chloro-4-(1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
141	2-chloro-4-(1-methyl-9,10-dihydro-3 <i>H</i> ,8 <i>H</i> -[1,4]dioxepino[2,3- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
142	2-chloro-4-[7-[(difluoromethyl)oxy]-1-methyl-8-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
143	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
144	2-chloro-4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-5-fluorophenol	
145	2-chloro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	
146	2-chloro-5-fluoro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	
147	2-chloro-4-[1-methyl-6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
148	2-bromo-4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-5-fluorophenol	
149	7-(3-chlorophenyl)-11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3- <i>f</i>]pyrazolo[3,4- <i>c</i>]isoquinoline	
150	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
151	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydrofuran-2-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
152	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydro-2 <i>H</i> -pyran-2-ylmethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
153	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(2,2,2-trifluoroethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

Table 3

Entry	Name	Structure
154	2-chloro-5-fluoro-4-[9-fluoro-1-methyl-6,7,8-tris(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
155	5-(3-chloro-4-hydroxyphenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
156	6,9-difluoro-5-(2-fluorophenyl)-1-methyl-8-{{[2-(methoxy)ethyl]oxy}}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinoline	
157	2-chloro-4-{8-[(difluoromethyl)oxy]-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
158	2-chloro-4-(6,11-difluoro-1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3- <i>g</i>]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-5-fluorophenol	
159	4-(1-methyl-3 <i>H</i> -benzo[e]indazol-5-yl)phenol	

Table 3

Entry	Name	Structure
160	6-fluoro-7-(2-fluorophenyl)-11-methyl-2,3-dihydro-9H-[1,4]dioxino[2,3-f]pyrazolo[3,4-c]isoquinoline	
161	2-chloro-4-{1-methyl-7-(methyloxy)-8-[(tetrahydro-2H-pyran-4-ylmethyl)oxy]-3H-pyrazolo[3,4-c]isoquinolin-5-yl}phenol	
162	2-chloro-4-[8-{[2-(ethyloxy)ethyl]oxy}-1-methyl-7-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
164	3-fluoro-4-(6-fluoro-11-methyl-2,3-dihydro-9H-[1,4]dioxino[2,3-f]pyrazolo[3,4-c]isoquinolin-7-yl)phenol	
165	2-chloro-5-fluoro-4-(6-fluoro-11-methyl-2,3-dihydro-9H-[1,4]dioxino[2,3-f]pyrazolo[3,4-c]isoquinolin-7-yl)phenol	
166	2-chloro-4-[8-(cyclopentyloxy)-1-methyl-7-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	

Table 3






Entry	Name	Structure
167	2-chloro-4-(1-methyl-7-(1-methylethyl)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
168	2-chloro-4-[9-ethyl-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
169	2-chloro-4-(6,9-difluoro-1-methyl-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
170	5-(3-chloro-4-hydroxyphenyl)-8-fluoro-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-6-ol	
171	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
172	2-chloro-4-(6-fluoro-1-methyl-8,9-bis{[2-(methoxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	
173	5-[3-chloro-4-(methoxy)phenyl]-6-fluoro-1-methyl-7-(methoxy)-8-[[1-methylpiperidin-4-yl)methyl]oxy}-3H-pyrazolo[3,4-c]isoquinoline	
174	5-[3-chloro-4-(methoxy)phenyl]-8-fluoro-1-methyl-7-(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-6-ol	
176	2-chloro-4-{6-fluoro-1-methyl-7-(methoxy)-8-[(2-piperidin-1-ylethyl)oxy]}-3H-pyrazolo[3,4-c]isoquinolin-5-yl}phenol	
177	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-7-(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
178	2-chloro-4-[8-{{2-(diethylamino)ethyl}oxy}-6-fluoro-1-methyl-7-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
179	2-chloro-4-(6-fluoro-1-methyl-7-(methoxy)-8-{{2-(methoxy)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
182	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{{(1-methylpiperidin-4-yl)methyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
183	2-bromo-4-(6-fluoro-1-methyl-9-(methoxy)-8-{{(1-methylpiperidin-4-yl)methyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
184	2-chloro-5-fluoro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{{(1-methylpiperidin-4-yl)methyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
185	4-(6-fluoro-1-methyl-9-(methyloxy)-8-[[1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-2-methylphenol	
186	2-chloro-4-{6,9-difluoro-1-methyl-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
187	2-chloro-4-(8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
188	2-chloro-4-(8-{[2-(diethylamino)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
191	6,9-difluoro-5-(1 <i>H</i> -indol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
193	5-(4-aminophenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	

Table 3







Entry	Name	Structure
194	2-chloro-4-(6-fluoro-1-methyl-7-(methoxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
195	5-(2-amino-1,3-thiazol-5-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
196	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
197	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
198	5-(6-aminopyridin-3-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
199	5-(5-amino-2-thienyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	

Table 3

Entry	Name	Structure
200	2-chloro-4-[8-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
201	2-chloro-4-(6-fluoro-1-methyl-9-(methoxy)-8-{[3-(4-methylpiperazin-1-yl)propyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
202	6,9-difluoro-5-(1 <i>H</i> -indol-6-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
203	N-[5-(6,9-difluoro-8-hydroxy-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-1,3-thiazol-2-yl]acetamide	
206	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
207	4-[8-({2-[butyl(ethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	

Table 3

Entry	Name	Structure
208	4-[8-{{(2 <i>R</i>)-2-amino-3-methylbutyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
209	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{{2-(1-methylpiperidin-4-yl)ethyl}oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
210	2-chloro-4-[8-{{(1-ethylpiperidin-4-yl)methyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
212	5-(5-amino-1,3,4-thiadiazol-2-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	
213	4-[8-{{(2 <i>R</i>)-2-amino-3,3-dimethylbutyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	

Table 3

Entry	Name	Structure
214	2-chloro-4-[6-fluoro-1-methyl-9-(methyloxy)-8-({2-[4-(2-methylpropyl)piperazin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
215	2-chloro-4-[8-{{2-(5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
216	2-chloro-4-[6-fluoro-1-methyl-8-({2-[4-(1-methylethyl)piperazin-1-yl]ethyl}oxy)-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
217	4-[8-{{2-(3-amino-8-azabicyclo[3.2.1]oct-8-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
218	2-chloro-4-[8-{{2-(1-ethylpiperidin-4-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
219	2-chloro-4-[8-{[2-(diethylamino)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
220	2-chloro-5-{6-fluoro-1-methyl-9-(methoxy)-8-[(2-pyrrolidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
223	2-chloro-4-[6-fluoro-1-methyl-8-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-9-(methoxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
224	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(3-pyrrolidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
225	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(3-piperidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

Table 3

Entry	Name	Structure
226	2-chloro-4-{6-fluoro-1-methyl-9-(methoxy)-8-[(3-morpholin-4-ylpropyl)oxy]-3H-pyrazolo[3,4-c]isoquinolin-5-yl}phenol	
227	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](methylamino)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl}]phenol	
228	2-chloro-4-[8-({2-[[2-(diethylamino)ethyl](methylamino)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl}]phenol	
229	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](ethylamino)ethyl]oxy}-6-fluoro-1-methyl-9-(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl}]phenol	
230	4-[8-[(2-{bis[3-(dimethylamino)propyl]amino}ethyl)oxy]-6-fluoro-1-methyl-9-(methoxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]-2-chlorophenol	

Table 3

Entry	Name	Structure
231	2-chloro-4-[6-fluoro-1-methyl-8-({2-[methyl(1-methylpyrrolidin-3-yl)amino]ethyl}oxy)-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
232	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-((2 <i>S</i>)-2-[(methyloxy)methyl]pyrrolidin-1-yl)ethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	
233	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{{2-(4-pyrrolidin-1-yl)piperidin-1-yl}ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
234	2-chloro-4-[8-{{2-(4-cyclohexylpiperazin-1-yl)ethyl}oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
235	2-[4-(2-{{5-(3-chloro-4-hydroxyphenyl)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-yl}oxy)ethyl)piperazin-1-yl]- <i>N</i> -(1-methylethyl)acetamide	

Table 3

Entry	Name	Structure
236	4-[8-{[2-(1,4'-bipiperidin-1'-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
237	2-chloro-4-[6-fluoro-1-methyl-8-{[2-(4-methyl-1,4-diazepan-1-yl)ethyl]oxy}-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
238	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
239	2-chloro-4-[8-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
240	2-chloro-4-[6-fluoro-1-methyl-9-(methyloxy)-8-[(2-thiomorpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
241	2-chloro-4-[8-{[2-(2,6-dimethylpiperidin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
242	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(octahydroquinolin-1(2 <i>H</i>)-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	
243	4-[8-({2-[bis(1-methylethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
244	4-[8-[(2-{bis[2-(methyloxy)ethyl]amino}ethyl)oxy]-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	
245	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	

52. (previously presented) A Compound selected from

9	4-[7,8-bis(methoxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]benzene-1,2-diol	
19	4-[7,8-bis(methoxy)-1-(1-phenylethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
24	4-[6,7,8-tris(methoxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
26	4-[8-(methoxy)-1-(phenylmethyl)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	
221	6,9-difluoro-5-(2-imino-3-methyl-2,3-dihydro-1,3-thiazol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	

53. (previously presented) A pharmaceutical composition comprising the compound according to claim 31 and a pharmaceutically acceptable carrier.

54. **(withdrawn-currently amended)** A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition according to claim 31.

55. **(withdrawn)** The method according to claim 54, wherein the kinase is ALK.

56. **(withdrawn)** The method according to claim 55, wherein modulating the *in vivo* activity of ALK comprises inhibition of ALK.

57. **(withdrawn-currently amended)** A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in ~~any one of~~ claims claim 31.

58. **(withdrawn)** The method of claim 57 where the disease is an ALK-positive lymphomas, B-cell lymphoma, neuroblastoma, or inflammatory myofibroblastic tumors.